Reports and Briefs on Respiratory in United Kingdom

Published within

« | 1 | 2 | » »|

Type Product title / description Pub Price
Report
Report

Market and Product Forecasts: Asthma – Premium products to offset loss to generics

Following several major market events, including the launch of anticipated generics, asthma market dynamics are changing. Moving from a history of strong growth stemming from combination products, the next 10 years will pose challenges.

Published By Datamonitor
07 Sep 2012 $6400
Buy
Report
Report

Epidemiology: Asthma – Stable prevalence rates in all age groups will lead to stable case numbers

Overview of asthma disease definition and a review of epidemiology literature. This report provides in-depth analysis of patient populations, a 10-year case forecast, and key patient segments across the seven major markets.

Published By Datamonitor
18 Jul 2012 $2800
Buy
Report
Report

Product Profiles: Asthma – Key companies act to maintain dominance

Asthma is a well established market, but key unmet needs continue to drive development. While Advair (fluticasone/salmeterol) has market dominance, GlaxoSmithKline is racing to bring a once-daily follow-on product to market ahead of generic entry.

Published By Datamonitor
01 Jun 2012 $6400
Buy
Report
Report

Product Profiles: COPD – Novel combinations race to the finish

Key unmet needs in the COPD market are driving development. While Spiriva (Boehringer Ingelheim) and Advair (GlaxoSmithKline) have market dominance, a number of pipeline products threaten their position.

Published By Datamonitor
18 May 2012 $6400
Buy
Report
Report

R&D Trends: Allergic Rhinitis – Immunotherapy dominates the pipeline

Overview of the allergic rhinitis pipeline, from preclinical to preregistration, with analysis by phase and formulation, as well as discussion of clinical trial design and trends. The future of treatment is assessed based on progress in development.

Published By Datamonitor
20 Apr 2012 $2800
Buy
Report
Report

R&D Trends: Asthma – Extensive investment in novel targets

From preclinical to preregistration, 139 products are in development for asthma. These are analyzed by phase and formulation, and clinical trial trends are discussed. The future of treatment is assessed, as are innovative early-stage approaches.

Published By Datamonitor
17 Apr 2012 $2800
Buy
Report
Report

R&D Trends: COPD – Simplified therapies are gaining traction

From preclinical to preregistration, 109 products are in development for COPD. These are analyzed by phase and formulation, and clinical trial trends are discussed. The future of treatment is assessed as are innovative early-stage approaches.

Published By Datamonitor
14 Mar 2012 $2800
Buy
Report
Report

Market and Product Forecasts: COPD – Growth expected despite untapped market potential

With significant new products, including Arcapta Neohaler and Daliresp, and numerous pipeline candidates forecast to launch, the COPD market is changing. Datamonitor’s patient based forecast estimates a growing market, despite generic erosion.

Published By Datamonitor
28 Nov 2011 $6400
Buy
Report
Report

Product Profiles: Asthma/COPD – Novel combinations edge closer to market

Key unmet needs remain in these established markets which are driving development. While Advair (GlaxoSmithKline) and Spiriva (Boehringer Ingelheim) have market dominance, a number of pipeline products threaten their position.

Published By Datamonitor
28 Oct 2011 $6400
Buy
Report
Report

R&D Trends: Cystic Fibrosis – New drugs tackle both cause and effect

Overview of the cystic fibrosis pipeline, preclinical to preregistration, with analysis by class, phase, and company. Recent changes in clinical trial design are discussed, and likely trends in the future of cystic fibrosis research are highlighted.

Published By Datamonitor
19 Oct 2011 $2800
Buy

« | 1 | 2 | » »|

No help is available.